Once dismissed as dangerous hallucinogens, psychedelic substances such as psilocybin, ketamine, and MDMA are now reshaping the landscape of modern psychiatry. Across the United States and beyond, clinical research is uncovering their potential to treat mental illnesses like depression and post-traumatic stress disorder (PTSD), conditions that have long resisted conventional treatments. The U.S. Food and Drug Administration (FDA) announced in May 2023 that it would review psilocybin-based treatments for treatment-resistant depression, marking a remarkable shift in how both medicine and society view psychedelics.

At Johns Hopkins University in Baltimore, a research team led by psychiatrist Dr. Stephen Ross reported that more than 70% of PTSD patients participating in MDMA-assisted psychotherapy showed lasting improvement after just a few guided sessions. Similar studies in institutions such as Imperial College London and the Multidisciplinary Association for Psychedelic Studies (MAPS) have produced consistent results, prompting expectations that the FDA may grant full approval for MDMA and psilocybin therapies by the end of 2024. These findings have inspired growing optimism among clinicians, but also caution among regulators who must balance innovation with safety.

The scientific mechanism behind this “psychedelic renaissance” appears to lie in the brain’s remarkable capacity for neuroplasticity. Brain-imaging studies show that psilocybin and MDMA reduce overactivity in the brain’s default mode network—a system associated with rumination and negative self-focus—while enhancing communication across neural circuits. Patients often describe these sessions as emotional resets that help them break free from deeply ingrained patterns of fear or despair. “We are not simply masking symptoms,” Dr. Ross explained, “we are helping the brain relearn how to heal itself.”

Beyond the laboratory, the social and economic implications are equally significant. Analysts estimate that psychedelic-based therapies could generate up to $6 billion in global revenue by 2030, attracting intense interest from pharmaceutical and biotech companies such as Compass Pathways and MAPS Public Benefit Corporation. Yet this commercialization has also sparked ethical debate. Critics warn that profit-driven expansion could lead to unregulated “ketamine clinics” and exploit vulnerable patients without adequate psychological supervision. Policymakers now face the challenge of ensuring that these treatments remain both scientifically sound and socially equitable.

Culturally, the reemergence of psychedelics marks a profound change in how society perceives mental illness. For decades, substances like LSD and psilocybin were symbols of counterculture and rebellion; now, under strict medical control, they are being reframed as legitimate tools for healing. This transformation blurs the boundary between chemistry and therapy, demanding new ethical standards for psychiatric care. As Dr. Rachel Yaden of Imperial College London noted, “We are entering an era where empathy and neuroscience must evolve together. Psychedelics are not miracles, but they remind us that healing the mind sometimes requires expanding it.”

With FDA approval likely within the next two years, psychiatry may soon witness a paradigm shift as dramatic as the introduction of antidepressants in the 1950s. The question that remains is not only whether psychedelics can heal, but whether society is ready to accept that true recovery may come from confronting the very substances it once feared.

오수정 강남포스트 학생기자  webmaster@ignnews.kr

<저작권자 © 강남포스트, 무단 전재 및 재배포 금지>